← Eichor
Study identifier: NCT03246802 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Partial Prostate Salvage High Dose Rate Brachytherapy

Condition: Recurrent Prostate Cancer  ·  Sponsor: British Columbia Cancer Agency

PhaseNA
Planned participants30
Who can joinMale, 45 Years to no upper limit
Healthy volunteersNo

About this study

A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of inability to deliver sufficient dose through external beam techniques. These patients respond well to re-irradiation using brachytherapy with about 50% of selected patients remaining free of recurrence 5 years after salvage. Advanced imaging using multiparametric Magnetic Resonance Imaging (mpMRI) allows identification of the site of recurrence, permitting partial prostate salvage brachytherapy. There is extensive literature on Low Dose Rate salvage brachytherapy but less on High Dose Rate.

This description comes directly from the study's public registry record.

Talk to the study team

Juanita Crook, MD  ·  2507123958  ·  jcrook@bccancer.bc.ca

Always discuss trial participation with your own doctor first.

Locations (1)

BCCA Center for the Southern InteriorKelowna, British Columbia, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03246802